Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification

por Sun, Xuqi, Li, Lingling, Lyu, Ning, Mu, Luwen, Lai, Jinfa, Zhao, Ming
Publicado 2020

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)

por Xiang, Zhanwang, Li, Guohong, Mu, Luwen, Wang, Haofan, Zhou, Churen, Yan, Huzheng, Huang, Mingsheng
Publicado 2023

The Clinical Value of Computed Tomography (CT)-Guided (125)I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

por Xiang, Zhanwang, Zhong, Zhihui, Mu, Luwen, Li, Guohong, Zhou, Churen, Wang, Haofan, Huang, Mingsheng
Publicado 2021

Mechanism and prognostic value of indoleamine 2,3‐dioxygenase 1 expressed in hepatocellular carcinoma

por Li, Shaolong, Han, Xue, Lyu, Ning, Xie, Qiankun, Deng, Haijing, Mu, Luwen, Pan, Tao, Huang, Xin, Wang, Xia, Shi, Yuanyuan, Zhao, Ming
Publicado 2018

Chiral ruthenium(ii) complex as potent radiosensitizer of (125)I through DNA-damage-mediated apoptosis

por Bai, Mingjun, Zeng, Zhaolin, Li, Li, Wu, Qiong, Zhang, Yanyang, Pan, Tao, Mu, Luwen, Zhu, Duo, Guan, Shouhai, Xie, Qiang, Mei, Wenjie
Publicado 2018

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study

por Lyu, Ning, Kong, Yanan, Li, Xiaoxian, Mu, Luwen, Deng, Haijing, Chen, Huiming, He, Meng, Lai, Jinfa, Li, Jibin, Tang, Hailin, Lin, Youen, Zhao, Ming
Publicado 2020